Skip to main content

Finnegan neonatal abstinence scoring system: normal values for first 3 days and weeks 5–6 in non-addicted infants

Buy Article:

$51.00 plus tax (Refund Policy)


ABSTRACT Objective 

The neonatal abstinence scoring system proposed by Finnegan is used widely in neonatal units to initiate and to guide therapy in babies of opiate-dependent mothers. The purpose of this study was to assess the variability of the scores in newborns and infants not exposed to opiates during the first 3 days of life and during 3 consecutive days in weeks 5 or 6. Patients and methods 

Healthy neonates born after 34 completed weeks of gestation, whose parents denied opiate consumption and gave informed consent, were included in this observational study. Infants with signs or symptoms of disease or with feeding problems were excluded. A modified scoring system was used every 8 hours during 72 hours by trained nurses; 102 neonates were observed for the first 3 days of life and 26 neonates in weeks 5–6. A meconium sample and a urine sample at weeks 5–6 were stored from all infants to be analysed for drugs when the baby scored high. Given a non-Gaussian distribution the scores were represented as percentiles. Results 

During the first 3 days of life median scores remained stable at 2 but the variability increased, with the 95th percentile rising from 5.5 on day 1 to 7 on day 2. At weeks 5–6 median values were higher during daytime (50th percentile = 5, 95th percentile = 8) than night-time (50th percentile = 2, 95th percentile = 6, P = 0.02). Conclusion 

Scores increase from days 1–3 to weeks 5–6 and show day–night cycles with 5–6 weeks. Values above 8 can be considered pathological. This data may help to raise suspicion of narcotic withdrawal and to guide therapy.

Keywords: Finnegan; narcotic withdrawal; neonatal abstinence; newborn infants; normal values; opiates; score

Document Type: Research Article


Affiliations: 1: Division of Neonatology, Department of Obstetrics and Gynecology, University Hospital Zurich, Switzerland, 2: Institute for Clinical Chemistry, University Hospital Zurich, Switzerland

Publication date: March 1, 2010


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more